

AMENDMENTS TO THE CLAIMS

Claims 1 - 10. (canceled)

Claim 11 (Currently Amended): An aerosol formulation comprising a corticosteroid, a propellant vehicle, ~~a cosolvent~~, and an antioxidant,

wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and

wherein said ~~propellant~~ corticosteroid is completely dissolved in the propellant vehicle and said propellant consists of one or more hydrofluoralkanes and a cosolvent.

Claim 12 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is ascorbyl palmitate.

Claim 13 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is a tocopherol ester.

Claim 14 (Previously Presented): The pharmaceutical composition of claim 11, wherein said antioxidant is selected from the group consisting of ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and tocopherol esters.

Claim 15 (Previously Presented): The pharmaceutical composition of claim 11, wherein the corticosteroid is budesonide.

Claim 16 (Currently Amended): The pharmaceutical composition of claim 11, wherein the propellant vehicle is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof.

Claim 17 (Previously Presented): The pharmaceutical composition of claim 11, wherein said cosolvent is an alcohol.

Claim 18 (Previously Presented): The pharmaceutical composition of claim 17, wherein said alcohol is ethanol.

Claim 19 (Currently Amended): A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising

a corticosteroid, a propellant vehicle, ~~a cosolvent~~, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and wherein said ~~propellant~~ corticosteroid is completely dissolved in the propellant vehicle and said propellant consists of one or more hydrofluoralkanes and a cosolvent.

Claim 20 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein the corticosteroid is budesonide.

Claim 21 (Currently Amended): The pressurized metered dose inhaler according to claim 19, wherein said propellant vehicle is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof.

Claim 22 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said cosolvent is an alcohol.

Claim 23 (Previously Presented): The pressurized metered dose inhaler according to claim 22, wherein said alcohol is ethanol.

Claim 24 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said antioxidant is ascorbyl palmitate.

Claim 25 (Previously Presented): The pressurized metered dose inhaler according to claim 19, wherein said antioxidant is a tocopherol ester.

Claim 26 (Currently Amended): A method for the treatment of a bronchial disorder in a subject in need thereof comprising administering to said subject an aerosol formulation comprising

a corticosteroid, a propellant vehicle, ~~a cosolvent~~, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetoneide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide, and wherein said ~~propellant~~ corticosteroid is completely dissolved in the propellant vehicle and said propellant consists of one or more hydrofluoralkanes and a cosolvent.

Claim 27 (Previously Presented): The method according to claim 26, wherein said corticosteroid is budesonide.

Claim 28 (Currently Amended): The method according to claim 26, wherein said propellant vehicle is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

Claim 29 (Previously Presented): The method according to claim 26, wherein said cosolvent is an alcohol.

Claim 30 (Previously Presented): The method according to claim 29, wherein said alcohol is ethanol.

Claim 31 (Previously Presented): The method according to claim 26, wherein said antioxidant is ascorbyl palmitate.

Claim 32 (Previously Presented): The method according to claim 26, wherein said antioxidant is a tocopherol ester.

Claim 33 (New): The aerosol formulation according to claim 11, wherein the corticosteroid is selected from the group consisting of budesonide, ciclesonide, and rofleponide.

Claim 34 (New): The pressurized metered dose inhaler according to claim 19, wherein the corticosteroid is selected from the group consisting of budesonide, ciclesonide, and rofleponide.

Claim 35 (New): The pressurized metered dose inhaler according to claim 19, wherein at least a part of the inner surfaces of said pressurized metered dose inhaler is composed of stainless steel.

Claim 36 (New): The pressurized metered dose inhaler according to claim 35, wherein the entirety of the inner surfaces of said pressurized metered dose inhaler is composed of stainless steel.

Claim 37 (New): The pressurized metered dose inhaler according to claim 19, wherein at least a part of the inner surfaces of said pressurized metered dose inhaler is composed of anodized aluminum.

Claim 38 (New): The pressurized metered dose inhaler according to claim 37, wherein the entirety of the inner surfaces of said pressurized metered dose inhaler is composed of anodized aluminum.

Claim 39 (New): The pressurized metered dose inhaler according to claim 19, wherein at least a part of the inner surfaces of said pressurized metered dose inhaler is coated with an inert organic coating.

Claim 40 (New): The pressurized metered dose inhaler according to claim 39, wherein the inert organic coating is an epoxy-phenol resin coating.

Claim 41 (New): The pressurized metered dose inhaler according to claim 39, wherein the inert organic coating is a multifunctional resin coating composed of an epoxy-phenol-novolac resin or an epoxy-cresol-novolac resin.

Claim 42 (New): The pressurized metered dose inhaler according to claim 39, wherein the inert organic coating is a perfluoroalkoxyalcane resin or a fluorinated-ethylene-propylene polyether sulfone resin.

Claim 43 (New): The pressurized metered dose inhaler according to claim 39, wherein the entirety of the inner surfaces of said pressurized metered dose inhaler is coated with an inert organic coating.

Claim 44 (New): The pressurized metered dose inhaler according to claim 43, wherein the inert organic coating is an epoxy-phenol resin coating.

Claim 45 (New): The pressurized metered dose inhaler according to claim 43, wherein the inert organic coating is a multifunctional resin coating composed of a epoxy-phenol-novolac resin or a epoxy-cresol-novolac resin.

Claim 46 (New): The pressurized metered dose inhaler according to claim 43, wherein the inert organic coating is a perfluoroalkoxyalcane resin or a fluorinated-ethylene-propylene polyether sulfone resin.

Claim 47 (New): The method according to claim 26, wherein the corticosteroid is selected from the group consisting of budesonide, ciclesonide, and rofleponide.

Claim 48 (New): The method according to claim 26, wherein said administering is metered dose administration to the respiratory tract of said subject via oral inhalation.

Claim 49 (New): The method according to claim 26, wherein said aerosol formulation is contained within a pressurized metered dose inhaler comprising a container equipped with a metering valve.

SUPPORT FOR THE AMENDMENTS

Claims 1-10 were previously canceled.

Claims 11, 16, 19, 21, 26, and 28 have been amended.

Claims 33-49 have been added.

Support for the amendment of Claims 11, 16, 19, 21, 26, and 28 is provided by the specification throughout, for example at page 2, line 27 to page 3, line 3, page 6, lines 6-12, and the Examples. New Claims 33-49 find support in the originally filed Claims 1-10 and the specification as originally filed, for example at page 1, lines 3-8, page 1, lines 12-16, page 1, lines 19-21, page 4, line 26 to page 5, line 25, page 6, line 14 to page 9, line 1, page 9, line 13 to page 10, line 9, and the Examples.

No new matter is believed to have been added by these amendments.